X

Follicular Lymphoma

Follicular Lymphoma

Lack of Intrafollicular Memory CD4 + T Cells is Predictive of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

Lack of intrafollicular CD4 expression predicts early failure in FL and combined with FLIPI improves identification of high-risk patients.

Blood Cancer Journal
07/15/2021
Copanlisib Plus Rituximab Shows Superior Efficacy Over Monotherapy in FL, MZL

Copanlisib when given in combination with rituximab demonstrated superior efficacy when compared to rituximab monotherapy in patients with relapsed FL/MZL, per findings presented at ASH 2021.

Oncology Learning Network
06/15/2021
Role of Allogeneic HSCT Fading in Lymphoma Management

As targeted therapies and novel treatments emerge, allogeneic hematopoietic cell transplantation has taken a backseat to immunotherapy in the treatment of lymphoma.

Healio
07/17/2021

Intratumoral T Cells Have a Differential Impact on FDG-PET Parameters in Follicular Lymphoma

Pretherapy TMTV is reflective of the FL tumor cell burden within malignant nodes.

Blood Advances
06/22/2021
High Basal Maximal Standardized Uptake Value in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse

A simple and easily available parameter, such as SUVmax, could represent a useful tool in clinical practice to evaluate at diagnosis the risk of late relapse in follicular lymphoma.

Cancers
06/09/2021
Axicabtagene Ciloleucel Demonstrates Improvement Across Multiple Endpoints in Relapsed or Refractory Follicular Lymphoma

In the treatment of R/R FL, a comparison of data from the ZUMA-5 trial with those of the external control cohort of the SCHOLAR-5 trial show substantial improvement in all clinical endpoints with a

The ASCO Post
06/16/2021
'Impressive Results' With CAR T-cell in R/R Follicular Lymphoma

A new analysis suggests patients with R/R FL live longer when they are treated with the novel anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel than...

Medscape
06/15/2021
DC-SIGN Binding to Mannosylated B-cell Receptors in Follicular Lymphoma Down-Modulates Receptor Signaling Capacity

Investigators show that despite being of low-level, DC-SIGN induces a similar downstream transcriptional response to anti-IgM in primary FL cells, characterized by activation of pathways associated

Scientific Reports
06/03/2021
Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma

This study explores the efficacy of lenalidomide plus rituximab for patients with R/R DLBCL including cases of secondary CNS involvement and transformed FL in real-world context because...

Cancer Management and Research
05/28/2021
The Role of Tazemetostat in Relapsed/Refractory Follicular Lymphoma

Tazemetostat was recently approved for the treatment of patients with relapsed FL after 2 or more prior lines of therapy in the presence of an EZH2 mutation and for those without any other...

Therapeutic Advances in Hematology
05/27/2021
Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma

Emerging data with novel forms of immunotherapy suggest that immune-directed approaches can produce very high and potentially durable responses in FL/MZL with limited toxicities, further...

Cancer Management and Research
05/14/2021
Treatment Dependence of Prognostic Gene Expression Signatures in de novo Follicular Lymphoma

Study investigators evaluate the performance and treatment dependence of the published gene expression–based models in patients with first-line FL treated in the randomized, phase 3 GALLIUM study..

Blood
05/13/2021
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches—Focus on EZH2-Targeted Drugs

Epigenetic modifier gene mutations are common in patients with FL.

Current Oncology Reports
05/03/2021
The Value of Complete Remission According to Positron Emission Tomography Prior to Autologous Stem Cell Transplantation in Lymphoma: A Population-Based Study Showing Improved Outcome

CAR T-cell and bispecific antibody therapies will likely necessitate a reconsideration of the role of ASCT in lymphoma. Patients who are likely to profit from ASCT need to be better identified.

BMC Cancer
05/04/2021
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma

The ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up for Follicular Lymphoma released in the late 2020 in accordance with the ESMO standard operating procedures for...

Hemasphere
04/21/2021
Effect of Lisocabtagene Maraleucel on HRQoL and Symptom Severity in Relapsed/Refractory Large B-Cell Lymphoma

HRQoL and symptom improvements across prespecified EORTC QLQ-C30 scales were clinically meaningful in a notable proportion of patients.

Blood Advances
04/27/2021
Lenalidomide Triggers T-cell Effector Functions in vivo in Patients With Follicular Lymphoma

Lenalidomide induces early T-cell activation and reprogramming, and restores long-term immune synapse formation in vivo in FL patients.

Blood Advances
04/20/2021
Lack of Activation-Induced Cytidine Deaminase Expression in in situ Follicular Neoplasia

The immunoglobulin heavy chain genes undergo class switch recombination and somatic hypermutation to produce a diverse repertoire of high affinity antibodies.

Haematologica
04/01/2021
EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma

European Union approval has been recommended for duvelisib for patients with relapsed/refractory CLL or refractory FL who have received at least two prior lines of therapy.

Medscape
03/29/2021
3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma

Study investigators report a realistic 3D model of t (14;18)-positive B-NHL cell culture, which monitored by state-of-the-art 2D and 3D imaging, allows more robust drug testing.

Cancers
03/24/2021
Impact of Transformation on the Survival of Patients Diagnosed With Follicular Lymphoma That Progressed Within 24 Months

This study investigates the occurrence of transformation and its association with POD24 in FL patients receiving RCVP, RCHOP, and BR.

Journal of Cancer
03/05/2021
Inhibitory Effects of Periplocin on Lymphoma Cells: A Network Pharmacology Approach and Experimental Validation

The effects of periplocin on lymphoma and the underlying mechanisms of action remain unclear.

Drug Design, Development and Therapy
03/26/2021
The Imbalance of Circulating Follicular T Helper Cell Subsets in Primary Sjögren’s Syndrome Associates With Serological Alterations and Abnormal B-Cell Distribution

This study investigates whether a change in the balance of circulating TFH subsets and follicular regulatory T cells could affect the distribution of B cells in pSS. 

Frontiers in Immunology
03/19/2021
Karonudib Has Potent Anti-Tumor Effects in Preclinical Models of B-Cell Lymphoma

Study investigators test the efficacy of karonudib in vitro and in preclinical B-cell lymphoma models. 

Scientific Reports
03/18/2021
Heat Shock Proteins in Lymphoma Immunotherapy

Immunotherapy harnessing the host immune system for tumor destruction revolutionized oncology research and advanced treatment strategies for lymphoma patients.

Frontiers in Immunology
03/18/2021
Outcomes of Older Patients With Follicular Lymphoma

Older patients with FL have similar early disease outcomes to younger patients. Age alone should not disqualify older FL patients from standard treatments or RCTs.

Blood Advances
03/22/2021
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives

Ongoing studies of copanlisib in combination with rituximab and standard-of-care chemotherapy in patients with relapsed indolent lymphoma have the potential to support the use of copanlisib...

03/09/2021
Targeted Treatment of Follicular Lymphoma

Recent advances in understanding of the unique genetic and immune biology of FL have led to increasingly potent and precise novel targeted agents, suggesting that a CT-future...

Journal of Personalized Medicine
02/22/2021
FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

On March 5, the FDA granted accelerated approval to axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

The ASCO Post
03/08/2021
Complete Remission of Follicular Lymphoma After SARS-CoV-2 Infection: From the “Flare Phenomenon” to the “Abscopal Effect”

This article describes a 61-year-old patient affected from FL, where end-of-treatment [18F]FDG-PET/CT (panel B) revealed bilateral pneumonia suggestive for COVID-19.

02/27/2021
Human Follicular Helper T Lymphocytes Critical Players in Antibody Responses

This review describes aspects of immunobiology and quantification of follicular helper T lymphocytes and circulating follicular helper T lymphocytes...

02/25/2021
Unusual Presentation of Recurrent Follicular Lymphoma as Diffuse Granular Shadow

Although the frequency of recurrent FL presenting with diffuse granular shadow is uncommon, recurrent malignant lymphoma should be considered as a differential diagnosis in case...

02/22/2021
Overexpression of Aberrant Wnt5a and its Effect on Acquisition of Malignant Phenotypes in Adult T-Cell Leukemia/Lymphoma Cells

This study shows a dramatic increase of WNT5A gene expression in acute-type ATL cells compared with those of indolent-type ATL cells.

Scientific Reports
02/18/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834